ASCO 2023 Breast Cancer Clinical Trial Updates
Adding ribociclib to an aromatase inhibitor reduces recurrence risk by 25 % in early‑stage HR‑positive/HER2‑negative breast cancer and is safe and well‑tolerated.
The ASCO 2023 meeting presented the phase 3 NATALEE trial, showing that ribociclib with an aromatase inhibitor decreases recurrence risk by 25 % in early‑stage HR‑positive/HER2‑negative breast cancer, offering a new therapeutic option.
The data support the routine use of ribociclib plus endocrine therapy in early‑stage HR‑positive/HER2‑negative breast cancer, potentially improving patient outcomes and expanding treatment choices.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC